|Hyaluronan-Based Nanocarriers with CD44-Overexpressed Cancer Cell Targeting|
|S. S. Song; H. Qi; J. W. Xu; P. Guo; F. Chen; F. Li; X. G. Yang; N. C. Sheng; Y. L. Wu; W. S. Pan
|Source Publication||Pharmaceutical Research
|Abstract||The objective of the work was to evaluate the potential of hyaluronan-based nanoparticles as tumor-targeting nano-systems for CD44-overexpressed cancer therapy. The synthesized amphiphilic cholesteryl succinoyl hyaluronan (Chol-Suc-HA) conjugates self-assembled into docetaxel(DTX)-loaded nanoparticles in the aqueous environment. The physiochemical properties of Chol-Suc-HA-DTX NPs were characterized. The in vitro cytotoxicity of Chol-Suc-HA-DTX NPs against MCF-7, 4T1, A549 and L929 cells was evaluated using MTT and LDH assays. Moreover, the cellular uptake mechanism was investigated using the CLSM and flow cytometry. The in vivo animal experiments of Chol-Suc-HA-DTX NPs including pharmacokinetic evaluation, bio-distribution observed by EX vivo NIRF imaging and antitumor efficacy were also carried out in SD rats or 4T1 tumor-bearing BALB/c mice. The self-assembled Chol-Suc-HA-DTX NPs with different degree of substitution (DS) of hydrophobic moiety exhibited high drug loading, uniform particle size distribution and excellent in vitro stability. However, the plasma stability of Chol-Suc-HA-DTX NPs was significantly influenced by the DS of hydrophobic moiety. The higher the DS was, the more stable the NPs were. Cellular uptake demonstrated that Chol-Suc-HA-DTX NPs were internalized into cancer cells via CD44 receptor-mediated endocytosis. Compared with TaxotereA (R), Chol-Suc-HA-DTX NPs displayed remarkably higher cytotoxicity to CD44-positive cancer cells (MCF-7, 4T1, A549 cells). In vivo animal experiments confirmed that Chol-Suc-HA-DTX NPs with relatively high DS values exhibited prolonged circulation time, excellent tumor-targeting properties and efficient antitumor effects with extremely low systemic toxicity. In addition, blank Chol-Suc-HA NPs also slightly suppressed the tumor growth. Chol-Suc-HA NPs with a suitable DS value portend to be promising drug vehicles for systemic targeting of CD44-overexpressed cancers.|
; guo, pan
; chen, fen
; li, fei
; yang, xinggang
; pan, weisan] shenyang pharmaceut univ, sch pharm, shenyang 110016, peoples r china. [qi, huan
; xu, jingwen
; wu, yingliang] shenyang pharmaceut univ, coll life sci & biopharmaceut, shenyang 110016, peoples r china. [sheng, naicheng] univ chinese acad sci, inst met res, shenyang 110016, peoples r china.
; pan, ws (reprint author), shenyang pharmaceut univ, sch pharm, pob 122,103 wenhua rd, shenyang 110016, peoples r china.
Interference With Endogenous
S. S. Song,H. Qi,J. W. Xu,et al. Hyaluronan-Based Nanocarriers with CD44-Overexpressed Cancer Cell Targeting[J]. Pharmaceutical Research,2014,31(11):2988-3005.
S. S. Song.,H. Qi.,J. W. Xu.,P. Guo.,F. Chen.,...&W. S. Pan.(2014).Hyaluronan-Based Nanocarriers with CD44-Overexpressed Cancer Cell Targeting.Pharmaceutical Research,31(11),2988-3005.
S. S. Song,et al."Hyaluronan-Based Nanocarriers with CD44-Overexpressed Cancer Cell Targeting".Pharmaceutical Research 31.11(2014):2988-3005.
|Files in This Item:||
||There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.